MADRID, 18 (EUROPA PRESS)
Shares of Danish pharmaceutical company Novo Nordisk rose as much as 6% on the Copenhagen Stock Exchange on Monday after the pharmaceutical company reported that the U.S. Food and Drug Administration (FDA) had approved an additional indication for "Wegovy" for the treatment of liver disease.
According to the Danish company, the FDA has approved an additional indication for 'Wegovy' for the treatment of non-cirrhotic metabolic syndrome-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis.
The accelerated approval is based on the first part of the ESSENCE trial, in which Wegovy demonstrated statistically significant and superior improvement in liver fibrosis without worsening of steatohepatitis, as well as resolution of steatohepatitis without worsening of liver fibrosis, compared to placebo.
“Wegovy is now uniquely positioned as the first and only approved GLP-1 treatment for MASH, complementing the already demonstrated weight loss, cardiovascular benefits, and extensive evidence base for semaglutide,” said Martin Holst Lange, Executive Vice President, Chief Scientific Officer and Head of Research and Development at Novo Nordisk.
Novo Nordisk shares were up 5.65% at mid-session, having risen as much as 6% at the start of trading. However, so far this year, the Danish pharmaceutical company's shares have fallen by more than 46%.
